# Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Source: https://onco.cc/trials/nct03301168/  
OnCo record `nct03301168` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BPX-501 T cells in acute lymphoblastic leukaemia, acute myeloid leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.

## Summary

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant is a phase 1/2 interventional study registered as NCT03301168 by Bellicum Pharmaceuticals, with 120 participants enrolled, started 2014-04 and due to reach its primary completion in 2021-05-11. Interventions recorded: BPX-501 T cells and Rimiducid.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03301168
- Phase: 1/2
- Setting: Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT03301168: https://clinicaltrials.gov/study/NCT03301168

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct03301168.json